NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









biomodal

biomodal

Private
CambridgeHealthcare & Life Scienceshttps://biomodal.com/

Last Round

Series D

Nov 2, 2021

Total Funding Raised

$144.5M

Company Overview

biomodal is an omics-based life sciences technology and analytics company that develops multiomic sequencing solutions to capture genetic and epigenetic information from DNA samples.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

multiomicsepigenetic sequencingliquid biopsy6-base sequencinggenomic analysiscell-free DNAcfDNAbiomarker detectionepigeneticsnext-gen sequencingNGSoncology researchbioinformatics pipelineepigenetic clockmultiomics tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

biomodal Comparables

Compare biomodal with similar companies based on industry and business-model similarity.

biomodal comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Element Biosciences
78%
Watchmaker Genomics
77%
Illumina, Inc.
71%

biomodal Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DNov 2, 2021
GrantJan 1, 2020
Series CApr 2, 2018
Series BMar 14, 2016
Series AOct 29, 2014

Key People

Founding team and executive leadership

Peter Fromen

Chief Executive Officer

Executive Team

Fiona Stewart

Chief Financial Officer

Executive Team

biomodal Investors

Notable investors and investment history

biomodal investors
InvestorRounds
TemasekSeries D
GVSeries C, Series D, Series B
SynconaSeries A, Series B, Series C
European CommissionGrant
JIMCOSeries D
Sequoia CapitalSeries B, Series C, Series D
DNA CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Launched duet +modC and duet evoC solutions.

  • Nov 2, 2021

    $88M round led by Temasek.

biomodal Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

biomodal Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about biomodal's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range97
Year Founded2012
Last FundingNov 2, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.